azd-7762
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00413686)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase Chk1INHIBITOR
CHEK1 inhibitor
Development discontinued, part of Astra Zeneca's Open Innovation program
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1- Mol. weight
- 362.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2041933 ↗
Also known as
- 3-(carbamoylamino)-5-(3-fluorophenyl)-n-(3-piperidyl)thiophene-2-carboxamide
- 5-(3-fluorophenyl)-n-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide
- azd7762
- azd7762
- azd7762
- azd 7762
- azd-7762
- azd-7762
- azd-7762
- azd-7762
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00937664 | Phase 1 | Jul 1, 2009 | AstraZeneca, National Hospital Organisation Kyushu Cancer Centre |
| NCT00473616 | Phase 1 | May 1, 2007 | AstraZeneca |
| NCT00413686 | Phase 1 | Dec 1, 2006 | AstraZeneca |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2006 |
| National Hospital Organisation Kyushu Cancer Centre | Academic/Hospital | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1